Gene Silencing

Feeds:: Posts; Comments

« Neural Networks in Alzheimer’s

CAR-T Therapy in Leukemia (Updated) »

Gene Silencing

November 5, 2015 by larryhbern

Gene Silencing

Larry H. Bernstein, MD, FCAP, Curator

LPBI

Gene Silencing/Gene Editing

Agilent, Stanford Researchers Collaborate on Chemically Modified Guide RNAs for CRISPR/Cas9 Genome Editing in T Cells

A paper in Nature Biotechnology showed that the guide RNAs increased genome editing efficiency in human primary T cells and hematopoietic stem cells.

UMass Scientists Lead Effort to Excise Latent HIV With CRISPR/Cas9

The scientists fused Cas9 to zinc finger proteins to reduce off-target activity, essentially replacing the other nucleases that had been used with zinc fingers.

CRISPR Therapeutics, Vertex Pharmaceuticals Ink $105M Collaboration Deal

The partners will focus on developing gene editing-based treatments for cystic fibrosis and sickle cell disease, among other diseases.

New Study Finds Three More CRISPR Proteins With Genome Editing Potential

A study in Molecular Cellshows CRISPR-Cas9-like genome editing in human cells and suggests one protein could be an RNA-guided, RNA-cleaving endonuclease.

Researchers Use Gene Editing to Improve Red Blood Cell Production From Stem Cells

The work could potentially make lab-based blood production cost-effective, as well as improve the creation of specific cell populations from stem cells.